Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the…
PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence
PostEra, a biotechnology company specializing in artificial intelligence for preclinical drug discovery, today announced a multi-target collaboration with Amgen, a leading biotechnology company. The collaboration will leverage PostEra’s AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and…